In moves that continue to strengthen its affiliation with the healthcare industry, NVIDIA has added three new companies to its growing list of AI-based partnerships.
The tech company has partnered with clinical research services company IQVIA, genomics specialist Illumina, and Mayo Clinic. Along with a collaboration with research organisation Arc Institute, the collaborations were announced during the JP Morgan Healthcare Conference on 13 January.
Go deeper with GlobalData
Nvidia, the world’s most valuable company with a market cap of $3.33tn, has expanded its presence in the healthcare sector over the past few years. The company states that AI, accelerated computing and biological data coming together is “turning healthcare into the largest technology industry”.
A 2023 report by GlobalData predicts that global revenue for AI platforms across healthcare will reach $18.8bn by 2027, with Nvidia’s technological advancements in the field a key reason for the market’s growth. The newly announced partnerships are the first of 2025 as the tech company looks ahead to a year when it could see its share price soar even higher.
IQVIA will use Nvidia’s AI Foundry – a service that allows companies to build custom generative AI models – to create new solutions in clinical research workflows. IQVIA is also developing agentic AI solutions kitted out with Nvidia’s NIM and Blueprints software that will expedite research and clinical development. Agentic AI perceive, reason, and act within complex and multi-step tasks, and have been referred to as “digital employees”.
During a press briefing ahead of the conference, Nvidia’s healthcare vice president Kimberly Powell said: “Initially, we’re going to focus on clinical trials. This is the longest, most expensive workflow and drug and medical device development, our partnership will accelerate trial execution while significantly reducing administrative version burden through the deployment of agents of all kinds.”
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataThe partnership with Illumina aims to harness next-generation genomics to enhance drug discovery and human health. As part of the deal, Illumina will use Nvidia’s accelerated computing and AI toolsets for multiomics analysis and workflows. Illumina expanded its reach in the multiomics space with the acquisition of Fluent BioSciences and its single-cell research technology in July 2024. Nvidia said that its technology on Illumina’s platforms will help make analysis and insights of the human genome more accessible to life science researchers and pharmaceutical companies.
Illumina’s chief technology officer Steve Barnard said: “By combining Illumina’s expertise in genomics data and analysis with Nvidia’s powerful AI platforms, we aim to enable pharma and biotech companies to unlock their own multiomics data to uncover transformative insights and improve success rates in developing life-saving therapies.”
The collaboration with the Mayo Clinic aims to progress digital pathology – a field which has transformed disease diagnosis by speeding up and improving histological slide analysis. Mayo Clinic has built a platform using robotic scanning that has a created dataset of 20 million whole-slide images with ten million patient-associated records. The medical centre will deploy Nvidia’s Blackwell chip and imaging platform MONAI to handle the datasets.
Powell said in the briefing: “Our ultimate goal is to create a human digital twin – this is a dynamic digital representation, including medical imaging, pathology, health records, wearables…and this collaboration will be a cornerstone for new applications in drug discovery and diagnostic medicine.”
Nvidia now has over 3,500 healthcare members in its Inception programme, a free framework offered by the company to nurture startups and support co-marketing opportunities. Members of the ecosystem come from market segments such as digital health, surgical robotics, imaging, and biopharma, among others.
“We’ve added over 1,300 [members] just last year,” Powell said. “[Healthcare] is the singular, largest industry in the inception programme. Healthcare is a $10trn industry with over 30% of operating expenses dedicated to meeting the growing demand. To address this challenge, we need AI solutions of all kinds.”
